News

CNBC-TV18, 9 Nov, 14:21

Zydus Lifesciences, Granules India offer growth opportunities over next 3-5 years: Shanika Capital

Shanika Capital's Anmol Ganjoo identifies Zydus Lifesciences and Granules India as potential pharma winners, citing earnings growth, capital allocation and future opportunities.

Zydus Lifesciences+0.94%

Read the full story on CNBC-TV18

Headline, summary and picture belong to CNBC-TV18, from its public news feed. We don’t copy the article; the full text is on CNBC-TV18’s site. Prices: Yahoo Finance, delayed.

• Shanika Capital's Anmol Ganjoo sees Zydus Lifesciences, Granules India among potential pharma winner

  CNBC-TV18, 9 Nov, 13:30

  Zydus Lifesciences+0.94%
  

• Zydus Lifesciences' Saroglitazar shows higher MASH resolution rates than placebo in phase 2b trial

  CNBC-TV18, 6 Nov, 23:35

  Zydus Lifesciences+0.94%
  

• Why Sun Pharma Advanced Research shares surge 11% despite weak sentiments on D-Street; what's boosting medical stock?

  Mint, 9 Nov, 13:10

  

• Gland Pharma shares jump 7% to 52-week high; Nomura sees re-rating but Citi says 'sell'

  CNBC-TV18, 9 Nov, 12:46

  

• Pharma shares shine: Sai, Gland, Divi's, Laurus, Glenmark surge up to 9%

  Business Standard, 9 Nov, 12:23

  

• Up 118% in 6 months! This volume shocker pharma stock skyrockets 14% despite weak trends on Dalal Street Do you own?

  Mint, 9 Nov, 11:34